Biomagnetics Diagnostics Corp. is an advanced medical device and biotechnology company with a revolutionary diagnostics system and test kit testing technology for HIV, Hepatitis, H-Pylori, HPV, Tuberculosis and many other viruses, bacterium’s, toxins and diseases. The company focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, instead of the antibodies produced by the body’s immune system which may take anywhere from weeks to months to appear.

The company intends to follow the lead of established Western drugmakers and biotechs Merck & Co. (MRK), Wyeth (WYE), Eli Lilly & Co. (LLY), Schering-Plough (SGP), Novartis (NVS), Sanofi-Aventis (SNY), Genentech (DNA), Bristol Meyers Squibb (BMYS) and many others that are ramping up investments in China, India and Singapore. The company is currently working to establish a separate Chinese operating company that it intends to apply for listing on the Shenzhen or Hong Kong stock exchange.

Biomagnetics is also currently

• Blackstone (NYSE:BX) announced plans to list up to eight Blackstone-owned firms and sell at least five additional companies

• Barclays (NYSE:BCS) reported plans to spin off a $6.35 billion portfolio of complex credit assets as it seeks to clean up its balance sheet

• Phillips Electronics (NYSE:PHG) reported better-than-expected third quarter earnings, helped by cost-cutting measures, although the company said most markets are yet to see recovery

• Deutsche Bank (NYSE:DB) lifted Johnson & Johnson's (NYSE:JNJ) price target to $67 from $63 and maintained its "buy" rating on the stock, as the analyst noted "Ahead of Tuesdays earnings call we are raising our price target to $67 (prior $63) based on improving comparable multiples, new product approvals, stabilization in the global economy, and FX tailwinds all [of] which should add to earnings in 4Q and next year. We expect management will focus on continued healthy trends in its Medical Device & Diagnostic

This weekend, I’ll be speaking at the Mt. Vernon Research/Investor’s Daily Edge “Boom & Doom” conference in South Florida. During my presentations, I’ll offer the attendees my top five stocks that I believe will fare well, no matter whether we’re in a depression or expansion. Now, it wouldn’t be fair to the paying customers if I give you those top five stocks here. But what I can do is provide you with the stockpicking method to my (some say considerable) madness…

A Fat Pipeline… And An Even Fatter Dividend

Several of the stocks are in the healthcare sector - my specialized area of expertise.

Not only do I cover that sector for Mt. Vernon Research, I also believe that owning the right healthcare stocks is crucial for having a well-balanced portfolio.

While President Obama’s goal to make healthcare affordable for every American is noble, it’s difficult to execute

With stocks having been beaten down so badly these past few quarters, investors are getting tired of losing money. However, for those of us who are not about to retire, we have to allow some room for patience in our investing strategies. Investing in a company whose stock price appreciates year-over-year is optimal, but if you’ve got some time to spare, invest in companies that you know will be more valuable 10 to 15 years down the road. With heart disease persisting as the number one killer worldwide, you should be looking to prop up your portfolio over the long run with stocks dedicated to fighting heart disease . Combined with the aging world population, these two stocks are poised to capitalize on the declining health of the eldest generation:

Medtronic Inc.

Medtronic Inc. [MDT:

Zila, Inc. (ZILA) is dedicated to the prevention, detection and treatment of oral cancer and other periodontal diseases. The company’s flagship product, ViziLite Plus, is designed for the early detection of oral abnormalities that often lead to cancer. It is recognized as the first and only medical device that has been cleared by the FDA for use in a population at an increased risk for oral cancer.

The company also designs, manufactures and markets an entire suite of proprietary products that are sold directly to dental professionals for periodontal disease. These products include the Rota-Dent powered toothbrush, the Pro-Select ultrasonic scaler for the prevention and treatment of periodontal disease, and Pro-Den RX fluorides, rinses and gels.

Over the past few years, Zila’s stock has been steadily drifting lower. It appears to have made a base slightly below $0.20 and is robustly moving up. In their stock alert, Beacon Equity commented, “With revenues

SurModics, Inc. (NASD: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, recently announced that Merck & Co., Inc. has notified the company that it will discontinue the License and Research Collaboration Agreement the companies signed in June 2007. Shares of SurModics declined sharply earlier this week after the announcement. Merck’s decision triggers an additional $9 million payment to SurModics from Merck.

SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Clinical data on I-vation TA generated to date has provided strong support for the tolerability profile of I-vation TA, and more generally, that of the I-vation sustained delivery platform.

The president and chief executive officer of SurModics, Bruce Barclay, commented during a recent a conference call stating, “Merck’s decision was prompted by a strategic review of its business and

For the third straight quarter in a row, OmniComm Systems, a leader in integrated electronic data capture solutions for clinical trials, is reporting another landmark quarter for new business. The company has surpassed its previous best quarter and signed contracts through the first two quarters of 2008 totaling almost $12 million, which surpass all of the revenues brought in from last year’s signed contracts.

During the second quarter, OmniComm signed a long-term guaranteed contract with a major biotechnology company which helped to boost the company’s financials. They have also continued to increase their customer base by adding seven new clients to their customer list, and continue to see recurring business from their existing loyal customers, who have added five more trials. Finally, they have added six new partners to their very successful Preferred Partnership Programs.

“I couldn’t be happier with the current momentum and speed in which we continue to